Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization.

Publication date: Jan 22, 2025

Determining COVID-19 vaccination strategies presents many challenges in light of limited vaccination capacity and the heterogeneity of affected communities. Who should be prioritized for early vaccination when different groups manifest different levels of risks and contact rates? Answering such questions often becomes computationally intractable given that network size can exceed millions. We obtain a framework to compute the optimal vaccination strategy within seconds to minutes from among all strategies, including highly dynamic ones that adjust vaccine allocation as often as required, and even with modest computation resources. We then determine the optimal strategy for a large range of parameter values representative of various US states, countries, and case studies including retirement homes and prisons. The optimal is almost always one of a few candidate strategies, and, even when not, the suboptimality of the best among these candidates is minimal. Further, we find that many commonly deployed vaccination strategies, such as vaccinating the high risk group first, or administering second doses without delay, can often incur higher death rates, hospitalizations, and symptomatic infection counts. Our framework can be easily adapted to future variants or pandemics through appropriate choice of the compartments of the disease and parameters.

Open Access PDF

Concepts Keywords
Covid COVID-19
Future COVID-19 Vaccines
Intractable COVID-19 Vaccines
Prisons Humans
Vaccinating Pandemics
SARS-CoV-2
United States
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease MESH retirement
disease MESH death
disease MESH infection
disease MESH Infectious Diseases
disease MESH plague
pathway REACTOME Infectious disease
disease IDO infectious disease
disease IDO history
disease IDO process
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease IDO susceptibility
disease MESH influenza
disease MESH rabies
disease MESH obesity
disease MESH hypertension
disease MESH diabetes complications
disease MESH Complications
disease MESH diabetic neuropathy
disease IDO entity
disease IDO algorithm
drug DRUGBANK Ranitidine
disease IDO infected population
disease MESH emerging infectious diseases
disease IDO intervention
disease IDO facility
drug DRUGBANK Etoperidone
drug DRUGBANK L-Valine
disease MESH asymptomatic infection
drug DRUGBANK Cysteamine
disease IDO symptom
disease MESH reinfection
disease MESH breakthrough infections
disease IDO country
drug DRUGBANK Tretamine
drug DRUGBANK Guanosine
disease MESH Morbidity
disease MESH dengue
disease MESH Tuberculosis
pathway KEGG Tuberculosis

Original Article

(Visited 1 times, 1 visits today)